GlassScriptPhysician profile
Eugene C Oliveto
NPI 1811061203
$2,162.61
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $367 · 2021: $463 · 2022: $706 · 2023: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.91 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $322.70 | 2019-2023 | Rexulti |
| Allergan, INC. | $195.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.91 | 2019-2023 | Trintellix |
| Lundbeck LLC | $133.55 | 2020-2022 | |
| Novo Nordisk INC | $114.87 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $92.21 | 2020-2022 | |
| Amgen INC. | $90.73 | 2019-2022 | |
| Lilly USA, LLC | $87.49 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.71 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.25 | 2022 | |
| Jazz Pharmaceuticals INC. | $42.48 | 2021 | |
| Alkermes, INC. | $41.06 | 2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $38.72 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $38.30 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $34.69 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.56 | 2022 | |
| Eisai INC. | $32.04 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.41 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $21.63 | 2022 | |
| Almatica Pharma LLC | $21.28 | 2021 | |
| Sanofi Pasteur INC. | $16.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.22 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.63 | 2020 | |
| Mylan Specialty L.P. | $13.10 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.06 | 2023 | Quviviq |
| Irhythm Technologies, INC. | $12.75 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.52 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Oliveto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.